In conclusion, the SensiScreen® FFPE BRAF qPCR Assay will permit to have a more specific, time and cost saving approach to better characterize, and consequently to better treat, patients affected by MM, CRC and the other cancer types, for which BRAF characterization is fundamental for therapy decision. This evidence concerns the gene BRAF and cancer.